Dr. Moirar M. Leveille Launches Innovative Coaching Program and Book to Help Professionals Release Trauma and Eliminate Stress
Integrative Wellness Expert Introduces 12-Week Coaching Program and Companion Book Combining Natural Medicine, Mindfulness, and Neuroscience
BOSTON, May 23, 2025 /CNW/ -- Dr. Moirar M. Leveille, The Holistic Wellness Whisperer™, proudly announces the dual launch of her innovative MindfulYess Protocol and the empowerment book, The MindfulYess Guide: The Five Easy Ways to Redesign Your Life and Take Control of Your Destiny. This combined initiative empowers professionals aged 30–50 to overcome chronic stress and unresolved trauma using an integrative, science-backed, and spirit-led approach to personal transformation.
Stress and trauma are often hidden burdens for professionals, contributing to mental fog, emotional imbalance, and physical health issues. Dr. Leveille's 12-week MindfulYess Protocol integrates natural medicine, mindfulness, and neuroscience to promote deep, sustainable healing. The program boasts a 99% success rate in pilot testing and has already transformed the lives of over 1,000 clients worldwide.
Complementing the coaching program is The MindfulYess Guide, a practical and inspiring book that delivers actionable insights into wellness, authentic living, and alignment with one's higher purpose. Drawing from her journey of reversing an autoimmune condition and her renowned Table of Life framework, Dr. Leveille offers readers a roadmap to reduce stress, cultivate connection, and redesign their lives with intention and simplicity.
"This program and the book aren't just about managing stress—it's about mastering your peace, rewriting your story, and reconnecting with the powerful self within you," says Dr. Leveille. "Our goal is to provide professionals with the tools and support necessary to navigate their healing journey effectively."
Program Highlights:
12-Week Structured Curriculum addressing the root causes of stress, trauma, and burnout
Holistic Methodology that blends coaching, neuroscience, mindfulness, and natural medicine
Evidence-Based Success with a 99% transformation rate among program participants
The MindfulYess Protocol and The MindfulYess Guide are now available, offering an integrated and transformative path for professionals seeking to lead more empowered, purposeful lives.
About Dr. Moirar M. Leveille
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions Français
The test, run on Abbott's portable i-STAT ® Alinity ® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussion The test produces lab-quality results in 15 minutes Clinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency room The test can be used to help evaluate patients up to 24 hours after injury MISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE: ABT) announced today that Health Canada has approved the company's i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests used to help assess mild traumatic brain injury (mTBI) were only authorized for use with plasma or serum, requiring samples to be sent to a lab for processing. This new authorization will enable testing to be performed in an array of new healthcare settings beyond hospital emergency departments, including urgent care clinics. This is an important step toward a future where testing could be done in settings such as in pharmacies, clinics without radiology or even in locations such as the sidelines of a sporting event. "Particularly in the emergency setting, we have long needed a reliable and expedient way to assess and triage patients for urgent computed tomography (CT) imaging of the brain after head trauma," said Andrew Beckett, M.D., a trauma surgeon and medical director of the Trauma Program at St. Michael's Hospital, Unity Health Toronto, and an associate professor at the University of Toronto. "The availability of a rapid point of care and objective test for traumatic brain injury will be a major advancement in emergency care as it can help facilitate immediate and precise diagnosis, ensuring prompt, appropriate treatment." The whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older who present with suspected mTBI, commonly known as a concussion. Test results can help rule out the need for a CT scan of the head and assist in determining the best next steps for patient care in conjunction with other clinical information. The ability to perform the test with a whole blood sample means testing can take place in healthcare settings without a lab, which helps to accelerate head trauma evaluation. With this authorization, the i-STAT TBI test cartridge can be used to help evaluate patients up to 24 hours after injury, an important advancement since those injured often wait to seek care. It is estimated that 165,000 Canadians will experience a TBI this year. 1 Likewise, each year in Canada, more than 20,000 people are hospitalized for TBI, which can range from mild to severe and include concussions. 2 Among all types of TBIs, concussions are the most common, accounting for approximately 80 to 95 percent of such injuries. 3 Even a mild form of TBI can have long-term consequences. 2 For decades, standard TBI assessment has remained the same, with doctors leveraging tools such as the Canadian CT Head Rule which uses the Glasgow Coma Scale, a subjective assessment as well as CT scans, to detect brain tissue damage or lesions. A blood test provides objective information and helps remove the ambiguity of a standard concussion assessment. "Abbott has pioneered breakthroughs in TBI testing technology for more than a decade," said Beth McQuiston, M.D., senior medical director in Abbott's diagnostics business. "We're proud of this important step forward in advancing the standard of care for concussions. With this approval, right from the patient's bedside, clinicians are now able to order a rapid blood test that can provide powerful objective information, quickly. This dramatically changes the efficiency in the emergency room and helps optimize patient care." This approval expands Abbott's TBI test on market offerings, which already includes the i-STAT TBI Plasma test and the ARCHITECT ® and Alinity i lab test (serum and plasma). How the test works: The i-STAT TBI test cartridge with the i-STAT Alinity System requires a small venous blood sample – just a few drops applied to the test cartridge. The cartridge is then inserted into the portable i-STAT Alinity instrument. The test measures two brain-specific biomarkers that are released into the blood stream when there is a significant brain injury. If neither of these biomarkers measured are above an established cutoff, a significant injury has likely not occurred, and a CT scan can likely be avoided. Testing for these two biomarkers – ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) – following an injury can provide essential and objective information about a patient's condition and can help healthcare providers decide an appropriate treatment plan. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at and on LinkedIn, Facebook, Instagram, X and YouTube. The i-STAT TBI test cartridge was developed with support by the U.S. Department of Defense U.S. Army Medical Research and Development Command's (USAMRDC) U.S. Army Medical Materiel Development Activity (USAMMDA). The USAMRDC has been dedicated to developing a solution for the objective detection and evaluation of TBI for more than two decades and has played a critical role in developing the TBI test on Abbott's i-STAT Alinity platform. (Reference to USAMRDC and USAMMDA does not imply or constitute endorsement by these organizations or by the Department of Defense or the U.S. Army.) The T ransforming R esearch and C linical K nowledge in T raumatic B rain I njury (TRACK-TBI) research team was the first to demonstrate how this TBI blood test can be used for the benefit of TBI patients in clinical care. 1 Brain Injury Canada. Statistics: Traumatic brain injury (TBI) general statistics. Available at Accessed on April 29, 2025. 2 Government of Canada. Injury in review, 2020 edition: Spotlight on traumatic brain injuries across the life course. Available at Accessed November 2024. 3 Statistics Canada. Self-reported concussions in Canada: A cross-sectional study. Available at Accessed November 2024.
Cision Canada
2 hours ago
- Cision Canada
VANFLYTA® is Now Approved in Canada Specifically for Adult Patients with Newly Diagnosed FLT3-ITD Positive AML Français
After ENHERTU ®, VANFLYTA ® is the second innovative medicine from the Daiichi Sankyo oncology pipeline to be available in Canada Approval based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival TORONTO, June 16, 2025 /CNW/ - Daiichi Sankyo's (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA maintenance monotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FMS-like tyrosine kinase 3-internal tandem duplication (FLT3 -ITD) positive. 1 Improvement in overall survival (OS) has not been demonstrated for maintenance monotherapy following allogeneic hematopoietic stem cell transplantation. 1 A validated test is required to confirm the FLT3 -ITD status of AML. 1 AML is one of the most common forms of leukemia in adults, representing approximately 80% of all cases. 2 FLT3 gene mutations occur in approximately 30% of newly diagnosed patients with AML. 3 Approximately 80% of these are FLT3 -ITD mutations, which drive cancer growth and contribute to an increased risk of relapse and shorter overall survival. 3,4 FLT3 -ITD mutations occur in roughly 25% of all AML cases, with some studies reporting a frequency as high as 30%. 3,4 The five-year survival rate for Canadian patients with AML receiving the current standard of care has been reported at approximately 23%. 5 VANFLYTA is a novel selective FLT3 -ITD inhibitor that when used in combination with standard chemotherapy and across all three phases of treatment: induction, consolidation and maintenance, provides proven survival outcomes in newly diagnosed FLT3 -ITD positive AML - even in a population of adults up to 75 years of age. 6 The approval of VANFLYTA by Health Canada was based on the results of the QuANTUM-First phase 3 clinical trial. In QuANTUM-First, VANFLYTA combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation and continued as maintenance monotherapy following consolidation, demonstrated a 22.4% reduction in the risk of death compared to standard chemotherapy alone (HR = 0.78 [95% CI: 0.62-0.98; 2-sided p=0.0324]) in patients with newly diagnosed FLT3 -ITD positive AML. 1,6 Median OS was 31.9 months for patients receiving VANFLYTA (n=268; 95% CI: 21.0-NE) compared to 15.1 months for patients in the control arm (n=271; 95% CI: 13.2-26.2) at a median follow-up of 39.2 months. 6 "The approval of VANFLYTA in Canada represents a significant advancement for the treatment of patients with newly diagnosed FLT3 -ITD positive AML, which is one of the most aggressive and difficult-to-treat subtypes," said Brian Leber, MD, FRCP, Professor of Medicine, Department of Medicine, McMaster University. "In the QuANTUM-First trial, VANFLYTA added to standard chemotherapy and continued as maintenance resulted in longer remission and prolonged overall survival and it will be a much needed new treatment option that has potential to change the way FLT3 -ITD positive AML is treated." QuANTUM-First evaluated the safety profile in 265 patients with newly diagnosed FLT3 -ITD positive AML treated with VANFLYTA. The most common grade 3 or 4 adverse reactions (incidence ≥ 5%) were febrile neutropenia, sepsis, neutropenia, thrombocytopenia, fungal infections and anemia. 1,6 Cardiac events, such as QT prolongation and rare ventricular arrhythmias, also were observed. 6 "Despite recent advances in AML treatment, patients with AML bearing FLT3 -ITD mutations still face a challenging prognosis," said Andre Schuh, MD, FRCPC, Clinician Investigator, Cancer Clinical Research Unit, Princess Margaret Cancer Centre. "The approval of VANFLYTA offers a promising step forward, bringing hope for better outcomes in this high-risk patient population. Results from the QuANTUM-First trial demonstrated that combining VANFLYTA with standard chemotherapy and continuing it as maintenance therapy, led to deeper, more durable remissions and improved overall survival. As a new option for newly diagnosed FLT3 -ITD positive AML, VANFLYTA has the potential to redefine how this aggressive disease is treated in Canada." "The approval of VANFLYTA in Canada enables patients diagnosed with FLT3 -ITD-positive acute myeloid leukemia to receive a targeted therapy specifically developed for their disease subtype," said Fatih Yedikardeş, Country Manager Canada, Daiichi Sankyo. "This milestone reflects our commitment to transforming cancer therapy, advancing innovation in hematology and oncology and creating new standards of care for patients." About QuANTUM-First QuANTUM-First is a randomized, double-blind, placebo-controlled, global phase 3 study evaluating VANFLYTA versus standard chemotherapy on overall survival in adult patients aged 20-75 with newly diagnosed FLT3 -ITD positive AML. The primary endpoint of the study was OS. Secondary endpoints included event-free survival, post-induction rate of complete remission (CR), composite complete remission (CRc) and the percentage of patients who achieve CR or CRc with FLT3 -ITD measurable residual disease negativity. Safety and pharmacokinetics, along with exploratory efficacy and biomarker endpoints, including duration of CR, also were evaluated. 6 QuANTUM-First enrolled 539 patients at 193 study sites across Asia, Europe, North America, Oceania and South America. For more information, visit About FLT3 -ITD Positive Acute Myeloid Leukemia Approximately 487,000 new cases of leukemia were diagnosed globally in 2022, leading to more than 305,000 deaths. 7 AML accounts for approximately 23% of total leukemia cases worldwide. 8 The disease arises from the abnormal proliferation and differentiation of myeloid stem cells in the bone marrow. 2 In Canada, 1,286 people died from AML in 2022 and it remains the second most commonly diagnosed blood cancer in the country. 9,10 About VANFLYTA VANFLYTA is an oral, highly potent and selective type II FLT3 inhibitor approved in more than 30 countries in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherapy following consolidation, for the treatment of adult patients with newly diagnosed AML that is FLT3 -ITD positive based on the results from the QuANTUM-First trial. 1,3 VANFLYTA is an investigational medicine in all countries outside of Canada, Hong Kong, EU, Switzerland, Scotland, United Kingdom, Japan, and the U.S. About the VANFLYTA Clinical Development Program The VANFLYTA clinical development program includes the QuANTUM-Wild phase 3 trial in adult patients with newly diagnosed FLT3 -ITD negative AML, a phase 1/2 trial in pediatric and young adult patients with relapsed/refractory FLT3 -ITD positive AML in Europe, Asia and North America and several phase 1/2 combination studies as part of a strategic collaboration with The University of Texas MD Anderson Cancer Center. About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit References LEGAL: © 2025 Daiichi Sankyo Pharma Canada Ltd. VANFLYTA is a registered trademark of Daiichi Sankyo Co., Ltd., used by Daiichi Sankyo Pharma Canada Ltd. under license.
Cision Canada
4 hours ago
- Cision Canada
SOGC Releases New National Guidance to Improve Care for Women After Early Pregnancy Loss Français
WHISTLER, BC, June 16, 2025 /CNW/ - Too many women in Canada are left to suffer in silence after early pregnancy loss, facing not only profound grief but also inadequate health care that lacks the compassionate support they urgently need. The Journal of Obstetrics and Gynaecology of Canada (JOGC) has released a new Clinical Practice Guideline on early pregnancy loss (EPL) that includes several new recommendations aimed at improving care for women in Canada. Unlike previous guidelines, which have focused on clinical advice to health practitioners, this one also calls for broader health system reforms, with recommendations to increase resources and take specific, concrete actions to make care for women who lose a pregnancy more responsive, compassionate and patient-centered. Early pregnancy loss is common, occurring in about 15 per cent of pregnancies, and it can lead to significant psychological distress, including post-traumatic stress disorder. Adverse mental health outcomes are common among women who lose a pregnancy, present in up to 30 per cent of patients. That's why the Society of Obstetricians and Gynaecologists of Canada (SOGC) is now advising that women who experience a pregnancy loss should be screened for depression and offered treatment or referral to a mental health care provider, if needed. Patients should also be advised and reassured by their providers that most early pregnancy loss is not preventable or treatable. Feelings of guilt or self-blame can be common, and clinicians should approach these losses with compassion. In addition, the guideline notes that language is important in EPL care and urges providers to steer away from using negative terminology to describe a pregnancy loss. To provide more specialized, comprehensive and compassionate EPL care, the SOGC's guideline also calls for more Early Pregnancy Assessment Clinics (EPACs) to be established across Canada. First introduced in the United Kingdom, EPACs have been found to improve quality of care, reduce wait times and cut costs. They also serve as an alternative to emergency departments for women experiencing symptoms of pregnancy loss. In addition, the SOGC's new EPL Guideline is calling for mifepristone and misoprostol to be made available free for all patients who choose medical management of their pregnancy loss, to avoid the need for an unnecessary surgical procedure. The SOGC's EPL Clinical Practice Guideline will be launched at the SOGC's Annual Clinical and Scientific Conference, taking place June 17–20, 2025, in Whistler, B.C. This year's conference program also includes a number of timely and relevant presentations, including: an overview of the current state of abortion care in the United States by Dr. Stella Dantas; a session on inequities in compensation and surgical wait times in women's health in Canada by Dr. Nicholas Leyland; and a panel discussion featuring representatives from some of the SOGC's international sister organizations on the top three challenges facing women's health, which will include Dr. Frank Louwen, president-elect of FIGO, the International Federation of Gynecology and Obstetrics. "Every woman who experiences early pregnancy loss should receive the best medical care possible, including compassionate support and the resources needed to help them heal. This guideline is a call to action to make that a standard across Canada, and to ensure that women's voices and experiences are heard and reflected in the care they receive. It is also a call for health systems to invest in structures and services like Early Pregnancy Assessment Clinics that provide compassionate and timely care for women." – Dr. Lynn Murphy-Kaulbeck, President, Society of Obstetricians and Gynaecologists of Canada.
